Bright Minds Biosciences Inc. (DRUG)

Despite the revenue miss, adjusted diluted earnings per share of $0.54 met expectations. The company has also lowered its full-year 2026 financial outlook, attributing this adjustment to reduced immigration testing demand and cautious spending by U.S. Life Sciences customers. Analyst firm Stifel res…

A company that should generate ... newer drug franchise typically doesn't trade at around 10 times forward earnings or FCF, unless the market is being short-sighted. Right now, Bristol Myers Squibb appears to be priced for stagnation. But if management can continue growing its newer portfolio while …

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Keurig Dr Pepper (NASDAQ:KDP) and the rest of the beverages, alcohol, and tobacco stocks fared in Q1.

Eli Lilly stock gains on positive obesity drug trial data

AbCellera Biologics Inc. stocks have been trading up by 11.93 percent amid heightened optimism over its drug discovery partnerships Key Takeaways Q1 2026 revenue jumped to $8.3M, almost double year over year and ahead of the $5.9M consensus, signaling renewed commercial traction at AbCellera.